




Fig. S1. Decision tree of pitavastatin.

Samples, number of cases at each node; rhabdomyolysis, rate of rhabdomyolysis cases at each node; value, number of rhabdomyolysis (+) and rhabdomyolysis (-) cases.

Table S1. Results of comparison test of blood creatine kinase and plasma myoglobin levels following pitavastatin administration.

Days	group	creatine kinase (Unit/L)	<i>P</i>-value
7	P	1320.0 ± 145.9	-
	PA	1478.4 ± 223.6	0.9169
	PV	1427.7 ± 144.7	0.9777
	AV	1272.0 ± 186.8	0.9991
	PAV	1344.8 ± 164.8	0.9999
14	P	1037.8 ± 171.9	-
	PA	1113.8 ± 132.5	0.9999
	PV	1301.7 ± 608.0	0.9952
	AV	1159.3 ± 210.3	0.9995
	PAV	3166.7 ± 1240.5	<0.05
Days	group	myoglobin (ng/mL)	<i>P</i>-value
14	P	12.19 ± 2.93	-
	PA	14.60 ± 5.15	0.9993
	PV	26.08 ± 9.48	0.7331
	AV	14.05 ± 1.86	0.9998
	PAV	40.24 ± 20.86	0.1691

Creatine kinase and myoglobin are expressed as mean ± standard error of the mean (SEM).

P: pitavastatin, PA: pitavastatin + allopurinol, PV: pitavastatin + valsartan, AV: allopurinol + valsartan, PAV: pitavastatin + allopurinol + valsartan. Statistical significance ($P < 0.05$) was examined by Dunnett's test for multiple comparison.